|
1
|
Li D, Huang Z and Zhong J: Hepatitis C
virus vaccine development: Old challenges and new opportunities.
Natl Sci Rev. 2:285–295. 2015. View Article : Google Scholar
|
|
2
|
Pawlotsky JM: Hepatitis C virus resistance
to direct-acting antiviral drugs in interferonfree regimens.
Gastroenterology. 151:70–86. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gardiner DF, Rodriguez-Torres M, Reddy KR,
Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath
PJ, Schwartz H, et al: Daclatasvir plus sofosbuvir for previously
treated or untreated chronic HCV infection. N Engl J Med.
370:211–221. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Humphreys I, Flaxman A, Brown A, Cooke GS,
Pybus OG and Barnes E: Global distribution and prevalence of
hepatitis C virus genotypes. Hepatology. 61:77–87. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bassett SE, Guerra B, Brasky K, Miskovsky
E, Houghton M, Klimpel GR and Lanford RE: Protective immune
response to hepatitis C virus in chimpanzees rechallenged following
clearance of primary infection. Hepatology. 33:1479–1487. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rollier C, Depla E, Drexhage JA, Verschoor
EJ, Verstrepen BE, Fatmi A, Brinster C, Fournillier A, Whelan JA,
Whelan M, et al: Control of heterologous hepatitis C virus
infection in chimpanzees is associated with the quality of
vaccine-induced peripheral T-helper immune response. J Virol.
78:187–196. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Osburn WO, Snider AE, Wells BL, Latanich
R, Bailey JR, Thomas DL, Cox AL and Ray SC: Clearance of hepatitis
C infection is associated with the early appearance of broad
neutralizing antibody responses. Hepatology. 59:2140–2151. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Frey SE, Houghton M, Coates S, Abrignani
S, Chien D, Rosa D, Pileri P, Ray R, Di Bisceglie AM, Rinella P, et
al: Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with
MF59 administered to healthy adults. Vaccine. 28:6367–6373. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ray R, Meyer K, Banerjee A, Basu A, Coates
S, Abrignani S, Houghton M, Frey SE and Belshe RB: Characterization
of antibodies induced by vaccination with hepatitis C virus
envelope glycoproteins. J Infect Dis. 202:862–866. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kong L, Giang E, Nieusma T, Kadam RU,
Cogburn KE, Hua Y, Dai X, Stanfield RL, Burton DR, Ward AB, et al:
Hepatitis C virus E2 envelope glycoprotein core structure. Science.
342:1090–1094. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Deng L, Zhong L, Struble E, Duan H, Ma L,
Harman C, Yan H, Virata-Theimer ML, Zhao Z, Feinstone S, et al:
Structural evidence for a bifurcated mode of action in the
antibody-mediated neutralization of hepatitis C virus. Proc Natl
Acad Sci USA. 110:7418–7422. 2010. View Article : Google Scholar
|
|
12
|
Kong L, Lee DE, Kadam RU, Liu T, Giang E,
Nieusma T, Garces F, Tzarum N, Woods VL Jr, Ward AB, et al:
Structural flexibility at a major conserved antibody target on
hepatitis C virus E2 antigen. Proc Natl Acad Sci USA.
113:12768–12773. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Das S, Mullick R, Kumar A, Tandon H, Bose
M, Gouthamchandra K, Chandra M, Ravishankar B, Khaja MN, Srinivasan
N, et al: Identification of a novel epitope in the C terminus of
hepatitis C virus-E2 protein that induces potent and cross-reactive
neutralizing antibodies. J Gen Virol. 98:962–976. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tedeschi V, Akatsuka T, Shih JW, Battegay
M and Feinstone SM: A specific antibody response to HCV E2 elicited
in mice by intramuscular inoculation of plasmid DNA containing
coding sequences for E2. Hepatology. 25:459–462. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Garrone P, Fluckiger AC, Mangeot PE,
Gauthier E, Dupeyrot-Lacas P, Mancip J, Cangialosi A, Du Chéné I,
LeGrand R, Mangeot I, et al: A prime-boost strategy using
virus-like particles pseudotyped for HCV proteins triggers broadly
neutralizing antibodies in macaques. Sci Transl Med. 3:94ra712011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li D, von Schaewen M, Wang X, Tao W, Zhang
Y, Li L, Heller B, Hrebikova G, Deng Q, Ploss A, et al: Altered
glycosylation patterns increase immunogenicity of a subunit
hepatitis C virus vaccine, inducing neutralizing antibodies which
confer protection in mice. J Virol. 90:10486–10498. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li D, Wang X, von Schaewen M, Tao W, Zhang
Y, Heller B, Hrebikova G, Deng Q, Sun Q, Ploss A, et al:
Immunization with a subunit hepatitis C virus vaccine elicits
pan-genotypic neutralizing antibodies and intrahepatic T-cell
responses in nonhuman primates. J Infect Dis. 215:1824–1831. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang X, Yan Y, Gan T, Yang X, Li D, Zhou
D, Sun Q, Huang Z and Zhong J: A trivalent HCV vaccine elicits
broad and synergistic polyclonal antibody response in mice and
rhesus monkey. Gut. Nov 27–2017.(Epub ahead of print). doi:
10.1136/gutjnl-2017-314870.
|
|
19
|
Draper SJ and Heeney JL: Viruses as
vaccine vectors for infectious diseases and cancer. Nat Rev
Microbiol. 8:62–73. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guo J, Mondal M and Zhou D: Development of
novel vaccine vectors: Chimpanzee adenoviral vectors. Hum Vaccin
Immunother. 14:1679–1685. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mak KY, Rajapaksha IG, Angus PW and Herath
CB: The adeno-associated virus-A safe and promising vehicle for
liverspecific gene therapy of inherited and non-inherited
disorders. Curr Gene Ther. 17:4–16. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen Q, Zhai H, Li X, Ma Y, Chen B, Liu F,
Lai H, Xie J, He C, Luo J, et al: Recombinant adeno-associated
virus serotype 9 in a mouse model of atherosclerosis: Determination
of the optimal expression time in vivo. Mol Med Rep. 15:2090–2096.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cabral-Miranda F, Nicoloso-Simões E,
Adão-Novaes J, Chiodo V, Hauswirth WW, Linden R, Chiarini LB and
Petrs-Silva H: rAAV8-733-mediated gene transfer of CHIP/Stub-1
prevents hippocampal neuronal death in experimental brain ischemia.
Mol Ther. 25:392–400. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Manning WC, Paliard X, Zhou S, Pat Bland
M, Lee AY, Hong K, Walker CM, Escobedo JA and Dwarki V: Genetic
immunization with adeno-associated virus vectors expressing herpes
simplex virus type 2 glycoproteins B and D. J Virol. 71:7960–7962.
1997.PubMed/NCBI
|
|
25
|
Kuck D, Lau T, Leuchs B, Kern A, Müller M,
Gissmann L and Kleinschmidt JA: Intranasal vaccination with
recombinant adeno-associated virus type 5 against human
papillomavirus type 16 L1. J Virol. 80:2621–2630. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nieto K, Kern A, Leuchs B, Gissmann L,
Müller M and Kleinschmidt JA: Combined prophylactic and therapeutic
intranasal vaccination against human papillomavirus type-16 using
different adeno-associated virus serotype vectors. Antivir Ther.
14:1125–1137. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ploquin A, Szécsi J, Mathieu C, Guillaume
V, Barateau V, Ong KC, Wong KT, Cosset FL, Horvat B and Salvetti A:
Protection against henipavirus infection by use of recombinant
adeno-associated virus-vector vaccines. J Infect Dis. 207:469–478.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lin J, Zhi Y, Mays L and Wilson JM:
Vaccines based on novel adeno-associated virus vectors elicit
aberrant CD8+ T-cell responses in mice. J Virol.
8:11840–11849. 2007. View Article : Google Scholar
|
|
29
|
Lin SW, Hensley SE, Tatsis N, Lasaro MO
and Ertl HC: Recombinant adeno-associated virus vectors induce
functionally impaired transgene product-specific CD8+ T
cells in mice. J Clin Invest. 117:3958–3970. 2007.PubMed/NCBI
|
|
30
|
Qiu Y, Tao L, Zheng S, Lin R, Fu X, Chen
Z, Lei C, Wang J, Li H, Li Q and Lei B: AAV8-mediated
angiotensin-converting enzyme 2 gene delivery prevents experimental
autoimmune uveitis by regulating MAPK, NF-κB and STAT3 pathways.
Sci Rep. 6:319122016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lin J, Calcedo R, Vandenberghe LH, Bell P,
Somanathan and Wilson JM: A new genetic vaccine platform based on
an adeno-associated virus isolated from a rhesus macaque. J Virol.
83:12738–12750. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mays LE, Vandenberghe LH, Xiao R, Bell P,
Nam HJ, Agbandje-McKenna M and Wilson JM: Adeno-associated virus
capsid structure drives CD4-dependent CD8+ T cell response to
vector encoded proteins. J Immunol. 182:6051–6060. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li X, Cao H, Wang Q, Di B, Wang M, Lu J,
Pan L, Yang L, Mei M, Pan X, et al: Novel AAV-based genetic
vaccines encoding truncated dengue virus envelope proteins elicit
humoral immune responses in mice. Microbes Infect. 14:1000–1007.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhu F, Chen T, Zhang Y, Sun H, Cao H, Lu
J, Zhao L and Li G: A novel adeno-associated virus-based genetic
vaccine encoding the hepatitis C virus NS3/4 protein exhibits
immunogenic properties in mice superior to those of an
NS3-protein-based vaccine. PLoS One. 10:e01423492015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xiao X, Li J and Samulski RJ: Production
of high-titer recombinant adeno-associated virus vectors in the
absence of helper adenovirus. J Virol. 72:2224–2232.
1998.PubMed/NCBI
|
|
36
|
Wang L, Calcedo R, Nichols TC, Bellinger
DA, Dillow A, Verma IM and Wilson JM: Sustained correction of
disease in naive and AAV2-pretreated hemophilia B dogs:
AAV2/8-mediated, liver-directed gene therapy. Blood. 105:3079–3786.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Dreux M and Cosset FL: Detection of
neutralizing antibodies with HCV pseudoparticles (HCVpp). Methods
Mol Biol. 510:427–438. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Guan J, Wen B, Deng Y, Zhang K, Chen H, Wu
X, Ruan L and Tan W: Effect of route of delivery on heterologous
protection against HCV induced by an adenovirus vector carrying HCV
structural genes. Virol J. 8:5062011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Roohvand F and Kossari N: Advances in
hepatitis C virus vaccines, part two: Advances in hepatitis C virus
vaccine formulations and modalities. Expert Opin Ther Pat.
22:391–415. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liang TJ: Current progress in development
of hepatitis C virus vaccines. Nat Med. 19:869–878. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rollier CS, Verschoor EJ, Verstrepen BE,
Drexhage JA, Paranhos-Baccala G, Liljeström P, Sutter G,
Arribillaga L, Lasarte JJ, Bartosch B, et al: T- and B-cell
responses to multivalent prime-boost DNA and viral vectored vaccine
combinations against hepatitis C virus in non-human primates. Gene
Ther. 23:753–759. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
von Delft A, Donnison TA, Lourenço J,
Hutchings C, Mullarkey CE, Brown A, Pybus OG, Klenerman P,
Chinnakannan S and Barnes E: The generation of a simian adenoviral
vectored HCV vaccine encoding genetically conserved gene segments
to target multiple HCV genotypes. Vaccine. 36:313–321. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Brady JM, Baltimore D and Balazs AB:
Antibody gene transfer with adeno-associated viral vectors as a
method for HIV prevention. Immunol Rev. 275:324–333. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gao GP, Alvira MR, Wang L, Calcedo R,
Johnston J and Wilson JM: Novel adeno-associated viruses from
rhesus monkeys as vectors for human gene therapy. Proc Natl Acad
Sci USA. 99:11854–11859. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Meola A, Tarr AW, England P, Meredith LW,
McClure CP, Foung SK, McKeating JA, Ball JK, Rey FA and Krey T:
Structural flexibility of a conserved antigenic region in hepatitis
C virus glycoprotein E2 recognized by broadly neutralizing
antibodies. J Virol. 89:2170–2181. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Vasiliauskaite I, Owsianka A, England P,
Khan AG, Cole S, Bankwitz D, Foung SKH, Pietschmann T,
Marcotrigiano J, Rey FA, et al: Conformational flexibility in the
immunoglobulin-like domain of the hepatitis C virus glycoprotein
E2. MBio. 8:e00382–17. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yuan G, Liu J, Hu C, Huang H, Qi M, Wu T,
Liang W, Li YP, Zhang YY and Zhou Y: Genotype distribution and
molecular epidemiology of hepatitis C virus in Guangzhou, China:
Predominance of genotype 1b and increasing incidence of genotype
6a. Cell Physiol Biochem. 43:775–787. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Law JL, Chen C, Wong J, Hockman D, Santer
DM, Frey SE, Belshe RB, Wakita T, Bukh J, Jones CT, et al: A
hepatitis C virus (HCV) vaccine comprising envelope glycoproteins
gpE1/gpE2 derived from a single isolate elicits broad
cross-genotype neutralizing antibodies in humans. PLoS One.
8:e597762013. View Article : Google Scholar : PubMed/NCBI
|
